Log in
Enquire now
IMV

IMV

IMV is a Canadian biopharmaceutical company focused on developing immunotherapies for serious human diseases using its proprietary lipid-based delivery system, which the company calls DPX.

OverviewStructured DataIssuesContributors

Contents

imv-inc.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
‌
CAR T-Cell therapy
Vaccine
Vaccine
Immunotherapy
Immunotherapy
Biomedical engineering
Biomedical engineering
Biopharmaceutical
Biopharmaceutical
Technology
Technology
Biology
Biology
...
Location
Cambridge, Massachusetts
Cambridge, Massachusetts
0
Quebec
Quebec
0
Dartmouth, Nova Scotia
Dartmouth, Nova Scotia
0
Halifax, Nova Scotia
Halifax, Nova Scotia
B2X
B2B
B2B
CEO
Andrew Hall (entrepreneur)
Andrew Hall (entrepreneur)
0
Founder
‌
Warwick Kimmins
‌
Brian E. Lowe
Pitchbook URL
pitchbook.com/profiles.../59853-61
Legal Name
IMV Inc.
Number of Employees (Ranges)
51 – 200
Phone Number
+190249218190
Full Address
130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia, B3B 2C4 Canada0
2875 Boulevard Laurier Delta 1, Suite 220 Québec, Québec, G1V 2M20
10 Rogers Street Suite 120 and 121 Cambridge MA 02142-12880
CIK Number
1,734,7680
Place of Incorporation
Canada
Canada
0
Investors
Fonds de solidarité FTQ
Fonds de solidarité FTQ
Lumira Ventures
Lumira Ventures
Founded Date
2000
Fax Number
+1 (902) 492-08880
Total Funding Amount (USD)
55,349,998
Latest Funding Round Date
January 3, 2022
Business Model
Commerce
Licensing
Stock Symbol
IMV0
Exchange
Nasdaq
Nasdaq
0
Board of Directors
‌
Brittany Davison
0
‌
Shermaine Tilley
0
‌
Julia Gregory
0
‌
Markus Warmuth
0
‌
Kyle Kuvalanka
0
‌
Michael P. Bailey
0
‌
Michael Kalos
0
Latest Funding Type
Private equity
Private equity
NAICS Code
325,4120
Patents Assigned (Count)
1
Country
United States
United States
0
Canada
Canada
0
Headquarters
New Canada, Nova Scotia
New Canada, Nova Scotia
0

Other attributes

Company Operating Status
Active
Contact Page URL
imv-inc.com/contact
Previous Name
Immunovaccine Inc.0
SIC Code
2,8340
Ticker Symbol
IMV

IMV Inc. is a clinical-stage pharmaceutical company developing an effective T cell-targeted immune therapy for cancer. The company has built a delivery platform (DPX) that generates targeted immune cells directly into the human body, which produces robust and sustained capabilities to destroy cancer.

Its lead drug candidate, Maveropepimut-S (DPX-Survivac), which has completed multiple Phase 1/1b trials successfully, has generated positive results in advanced recurrent ovarian cancer and Diffuse Large B Cell Lymphoma (DLBCL).

IMV's DPX Platform enables antigen-presenting cells (APCs) to be attracted to the injection site, facilitating antigen presentation to immune cells. All IMV's immunotherapies and vaccines candidates are formulated with the DPX platform, giving them the ability to generate, in vivo, a targeted, robust, and sustained immune response against cancer cells or viruses.

The company is partnering with pharmaceutical companies, government agencies, and academic research institutions for the purpose of research and development.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like IMV

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.